If construction is the heavy industry of public procurement, medicine is its conveyor belt. Between May 2023 and June 2026, Bulgaria signed 36,401 contracts for medical equipment, pharmaceuticals and consumables (CPV 33) — more than any other sector by count. By value the sector ranks second at €9.4 billion, but it is precisely the number of procedures that makes it the most active and most predictable market for suppliers.
Here the asymmetry between mean and median is even more glaring than in construction. The average contract value is €271,700, but the median is just €15,188. This is a market of thousands of small deliveries — a batch of laboratory reagents, a yearly supply of a specific drug, consumables for a single ward. A few large contracts for expensive equipment (scanners, accelerators, angiographs) pull the average up, but the real life of the market revolves around small, recurring orders.
For a supplier this is crucial: medicine rewards systematic participation. You don’t wait once a year for the big tender — you bid in dozens of procedures every month, and the winning strategy is operational discipline, not a single big score.
95% on price: the market with no grey zone
If one fact defines the entire sector, it is this: 95.1% of medical tenders are awarded on the “lowest price” criterion. That is practically the highest share of price-only awarding among the leading sectors, and it has dramatic consequences.
When price is the only criterion, a high-quality proposal earns no points at all. Everything comes down to two things: first — being admissible (meeting every technical requirement without exception), and second — being the cheapest. There is no compensation. A slightly better warranty, better service, a stronger reputation — none of it counts unless explicitly required. And conversely — the smallest deviation from the specification throws you out of the game, no matter how attractive your price is.
This combination makes medicine a market with zero tolerance for error. With an average of 3.6 bids submitted per tender (the highest competition among the five sectors) and a purely price-based criterion, the differences between bidders are often minimal — and the winner is the one who is simultaneously the cheapest and flawless on paperwork.
The administratively heaviest sector
An interesting quirk: the technical specification in medicine is short — 1.6 pages on average. That sounds like a relief, until you look at the other numbers. The contract notice averages 29.1 pages — the longest of any sector — and the average number of documents per tender is 93.6, nearly double that of construction.
The explanation lies in the structure of medical tenders. They are rarely for a single item. The typical procedure is split into dozens of lots — each nomenclature unit (a specific drug, a specific consumable) is a separate lot with its own specification, quantity and price table. That is where both the long notices (listing all lots) and the enormous document counts (forms for each lot) come from.
For the bidder this means a specific kind of challenge: not complex, but voluminous documentation. You don’t need to decipher a 71-page technical specification as in construction; you need to fill in dozens of price tables flawlessly, without a single arithmetic error, for every lot you bid on.
Where bids are lost: the five traps
The real exclusions in medicine paint a clear picture.
Incomplete technical conformity. Missing CE markings, registration certificates (with the Bulgarian Drug Agency or the relevant register), or full technical data for the offered product. Medical devices and pharmaceuticals are strictly regulated, and every proof of conformity must be present and valid.
Deviation from the specification. With 95% of awards decided on price, even a minimal mismatch — weight, concentration, packaging, shelf life — leads to disqualification. Committees are given no room for leniency.
Problems with origin and representation. Unclear origin of the goods, missing proof of representation/distribution rights, weaknesses in the logistics chain.
Arithmetic errors in the financial offer. This is perhaps the most treacherous trap. With dozens of nomenclature lots and complex price tables, a single error in a sum or a unit price sinks the bid. In our analysis we came across a classic example outside medicine, but fully applicable here: a bidder excluded over a discrepancy of three cents between the form and the total value. The contracting authority had set zero tolerance, and three cents were enough.
Weak warranty commitments. For equipment, a missing or vague warranty and post-warranty service commitment is a frequent cause of elimination.
Price dynamics: realistic, not predatory
Despite the total dominance of the price criterion, final prices in medicine do not collapse. The median deviation of contract value from the estimate is −4.8% — meaning winners typically bid less than 5% below the estimate. (The mean deviation in the data looks dramatic — over +600% — but that is a statistical artefact of framework agreements, where the estimated value is a ceiling, not actual spend; that is why the median is the meaningful figure.)
The conclusion is the same as in the other sectors, with a nuance: competition here is stronger (3.6 bids), so the pressure on price is real — but not catastrophic. Whoever meets the technical requirements flawlessly enters a price race in which −5% is usually enough.
The procedure: the heavy, formal regime
Medicine is awarded predominantly through the “open procedure” (about 78%) — the most formal and regulated regime under the Public Procurement Act, with the strictest deadlines and publicity requirements. Framework agreements are a rarity (0.1%), and European funding is low (4.3%) — medical supplies are paid for mainly out of the national and hospital budgets.
The open regime means long timelines and a lot of paperwork, but also predictability: the rules are clear, and a well-prepared supplier can follow them as routine.
Who buys and who wins
The medical market has a clear two-tier buyer structure. On one side are the university and large multi-profile hospitals — the leading university hospital alone has awarded contracts worth nearly €3.9 billion, making it the largest single buyer in the entire sector. On the other side is the Ministry of Health (€1.5 billion), which centralises large purchases of medicines and vaccines. The rest is spread across hundreds of hospitals, dispensaries and healthcare facilities around the country. This structure calls for two different approaches: the large centralised tenders require scale and logistics, the hospital ones — flexibility and local presence.
On the supplier side, the market is dominated by wholesale pharmaceutical distributors. Three giants hold an enormous share of drug supplies.
Their advantage lies in logistics and representation rights, not in price. For smaller and specialised suppliers (consumables, reagents, equipment), the opportunity is in the niches the giants do not focus on — specific devices, particular nomenclatures, narrowly specialised equipment.
The annual dynamics show a mature, stable market: after the 2024 start (€1.34 billion), the sector has maintained a high and even volume — unlike cyclical construction, medicine buys constantly, because hospitals never stop working.
The competition paradox
Here the data hides a surprise. Although medicine has the highest average competition (3.6 bids), in a large share of tenders there is no real contest at all.
How do the two fit together? The answer is in the structure: the large, attractive drug tenders attract many bidders (and lift the average), while the mass of small, specific nomenclatures — a rare drug, a narrow consumable, a specialised reagent — each attract a single supplier who holds the relevant representation rights.
For a supplier this is a key strategic map: focus on the lots where you are one of the few able to deliver. In the highly competitive segments, price will eat your margin; in the niche lots where you are the only qualified bidder, you win at the estimated price. The skilled medical supplier does not bid everywhere — they map where there is a real competitor and where there isn’t, and concentrate their efforts where admissibility, not price, is decisive.
Playbook for the medical supplier
-
Meet every point of the specification unambiguously and provably. With 95% of awards on price, conformity is the only threshold — but it is absolute.
-
Prepare an exhaustive evidence package. CE markings, registration certificates, test protocols, references — leave no room for doubt in the committee’s mind.
-
Automate the checking of your price tables. With dozens of lots, arithmetic is your real enemy. Verify every sum and every unit price down to the cent.
-
Participate systematically. The market has a median of €15 thousand per contract and thousands of procedures — you win on volume and routine, not on a single big tender.
-
Analyse the contracting authority. The history of its previous tenders, the winning suppliers and the typical price levels give you a realistic baseline for bidding.
-
Never skip the warranty commitment. For equipment, a clear service commitment is often the difference between admission and elimination.
The process: the heavy formal regime
The medical “open procedure” is the most regulated path under the Public Procurement Act, and the supplier must know it in detail. After the notice, the bidder prepares the offer in the CAIS EOP e-procurement platform, filling in a separate technical and price section for every lot (nomenclature) it bids on. This is where the operational complexity hides: in a tender with fifty nomenclatures, a supplier may bid on five, twenty or all of them — but for each it must demonstrate full conformity and a flawless price table. Submission, as everywhere, requires an electronic signature and meeting the deadline to the second.
The specific evidence in medicine is regulatory: registration of medical devices and pharmaceuticals in the relevant registers (Bulgarian Drug Agency), CE marking, declarations of conformity, quality certificates, proof of representation/distribution rights. Unlike construction, the weight here is not in turnover and track record, but in the regulatory impeccability of every offered product.
Regulatory traps and trends
With 95% of awards on price, Article 107 of the Public Procurement Act (non-conformity with the announced conditions) is the main guillotine — any deviation from the specification is grounds for exclusion, with no discretion left to the committee. Article 72 (abnormally low price) is active too: in the price race, aggressive bids easily fall below the threshold and require justification.
Three trends will reshape the market. First — centralisation: more and more supplies pass through a central purchasing body (for medicines and vaccines), shifting competition towards larger, national tenders and favouring suppliers with scale. Second — the generic wave: expiring patents and budget pressure are opening the market to cheaper generic and biosimilar products, creating opportunities for new suppliers. Third — e-health and traceability: requirements for electronic reporting, serialisation and drug traceability are growing, and suppliers with impeccable systems will hold the advantage. In a world where the medical market remains No. 1 by volume, those who combine regulatory impeccability with operational discipline will dominate.
Conclusion
Medical procurement is the busiest market in the country — a conveyor belt of 36 thousand contracts, most of them small, all of them decided on price. Here you don’t win with a brilliant technical proposal, because it doesn’t count; you win by being simultaneously flawless on paperwork and the cheapest. The administrative burden is real — nearly a hundred documents per tender — but it is voluminous, not complex. For a supplier with disciplined processes, automated price-table checking and an impeccable certificate package, this is the most predictable and rewarding market in Bulgarian public procurement. As long as they remember the three cents.
For exactly this kind of market — where admissibility decides everything — see our requirements ↔ documents check and competitor & history analysis.
Data: official OCDS dataset of the CAIS EOP platform, 36,401 contracts under CPV 33, May 2023 – June 2026. Statistics: own analysis. Values in euro.
